BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21123950)

  • 1. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.
    Hu Q; Gao F; Tian W; Ruteshouser EC; Wang Y; Lazar A; Stewart J; Strong LC; Behringer RR; Huff V
    J Clin Invest; 2011 Jan; 121(1):174-83. PubMed ID: 21123950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
    Wang WH; Duan JX; Vu TH; Hoffman AR
    J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
    Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
    Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
    Yun K; Fidler AE; Eccles MR; Reeve AE
    Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N'-methylurea.
    Sharma PM; Bowman M; Yu BF; Sukumar S
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9931-5. PubMed ID: 7937920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
    Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
    Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms tumor genes.
    Huff V; Saunders GF
    Biochim Biophys Acta; 1993 Dec; 1155(3):295-306. PubMed ID: 8268188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of Wilms tumor: from WT1 and microRNA to animal models.
    Tian F; Yourek G; Shi X; Yang Y
    Biochim Biophys Acta; 2014 Aug; 1846(1):180-7. PubMed ID: 25018051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.
    Taniguchi T; Sullivan MJ; Ogawa O; Reeve AE
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2159-63. PubMed ID: 7534414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
    Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
    J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.
    Drummond IA; Madden SL; Rohwer-Nutter P; Bell GI; Sukhatme VP; Rauscher FJ
    Science; 1992 Jul; 257(5070):674-8. PubMed ID: 1323141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.